Biocartis Group NV reconfirmed earnings guidance of 2022. For the period, the company expects to achieve full year product revenue of EUR 50 million - EUR 55 million, representing growth of 24% - 36% over full year 2021 revenue of EUR 40.5 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.29 EUR | +1.05% | -.--% | -.--% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-.--% | 29.58M | |
+73.22% | 12.38B | |
-20.31% | 7.81B | |
+5.91% | 6.72B | |
+12.78% | 5.39B | |
+38.73% | 5.03B | |
-16.79% | 4.72B | |
-22.01% | 4.06B | |
-29.59% | 2.68B | |
+52.11% | 2.59B |
- Stock Market
- Equities
- BCART Stock
- News Biocartis Group NV
- Biocartis Group NV Reconfirms Earnings Guidance of 2022